Ismael Ávila

DTx is here to stay, and many institutions like hospitals and pharmaceutical companies are increasing their interest for DTx, where there is a special use in chronic and behavioral disorders. But, nowadays it is tough to separate unproven or low-value applications from those with proven therapeutic value. Evidence on safety and efficacy are difficult to obtain what represent big barriers to access the market, but many opportunities are just around the corner. Enjoy the read of this brief Digital Therapeutic report! read more